Clinical trials · New York
Cancer clinical trials in New York
We’re tracking 1,365 recruiting cancer studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT04929223RecruitingPhase 1
Targeted drug study for metastatic colon or rectal cancer
This Phase 1 study tests targeted cancer treatments in people with metastatic colorectal cancer, using genetic “biomarker” results to match you to the right treatment group. It focuses first on safety, and also looks for early signs the treatment may work in specific tumor subgroups.
New Hyde Park, New YorkAges 18 years+ - NCT06703476RecruitingPhase 3
Surgery techniques study for bladder cancer
This trial compares two different surgical approaches during bladder removal surgery: using a stent or not, and using a drug called alvimopan or not. Alvimopan helps the bowels work normally after surgery.
Commack, New YorkAges 21 years+ - NCT06792695RecruitingPhase 2
Study of new treatments for colorectal cancer
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
Rochester, New YorkAges 18–130 - NCT04946370RecruitingPhase 1/Phase 2
Pembrolizumab plus prostate cancer drug, with or without radiation
This early-phase trial tests pembrolizumab (an immune therapy) plus an androgen-receptor–blocking prostate cancer drug, and possibly a targeted radiation treatment. It’s for men with prostate cancer that has spread and keeps worsening despite standard hormone therapy, aiming to shrink tumors and improve control of the disease.
New York, New YorkAges 18 years+ - NCT04965064RecruitingPhase 2
Neratinib plus capecitabine for HER2-negative breast cancer brain mets
This study tests whether neratinib plus capecitabine can slow or shrink breast cancer that has spread to the brain. It is for people whose cancer shows an “overactive HER2 signal” on a specific tumor test, even though their cancer is labeled HER2-negative.
Rochester, New YorkAges 18 years+ - NCT04970056Recruiting
Pancreatic cancer risk and early-detection registry study
This study builds a database of people at higher risk for pancreatic cancer (or certain early warning findings) to help find better ways to detect the disease early. You may be asked to complete health questionnaires and possibly donate a blood/saliva/swab sample.
New York, New YorkAges 18–90 - NCT05010031RecruitingPhase 2
Lower-dose radiation for metastatic cancer with an ATM mutation
This trial tests whether giving a lower dose of radiation can help control metastatic tumors that carry a specific genetic change in the ATM gene. It may reduce side effects by using less radiation, while still aiming to keep the tumor under control.
Harrison, New YorkAges 18 years+ - NCT05024097RecruitingPhase 2
New medicines with chemotherapy after short radiation for rectal cancer
This trial tests two new immune-related medicines (an anti–PD-1 drug and an adenosine blocker) added to standard chemotherapy after a short course of radiation for rectal cancer. It aims to improve cancer control while checking safety.
New York, New YorkAges 18–90 - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
New York, New YorkAges 18 years+ - NCT05061550RecruitingPhase 2
Targeted immune-plus-chemo treatment before and after lung surgery
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
Buffalo, New YorkAges 18–95 - NCT05076942RecruitingPhase 2
Study of sentinel lymph nodes in vulvar cancer
This Phase 2 study looks at how vulvar squamous cell cancer (SCC) spreads to the sentinel lymph node, and how findings may guide treatment. It focuses on specific early-stage tumor features and requires that cancer is found in the sentinel lymph node.
Commack, New YorkAges 18 years+ - NCT05095207RecruitingPhase 1/Phase 2
Abemaciclib and bicalutamide for HER2-negative metastatic breast cancer
This Phase 1/2 trial tests whether combining abemaciclib with bicalutamide can slow or shrink HER2-negative, androgen receptor–positive (AR-positive) metastatic breast cancer. It mainly looks at safety and side effects, and also whether the combination can help patients with this type of breast cancer.
New York, New YorkAges 18–90 - NCT05134779Recruiting
Study aims to tailor cancer treatment to your biology
This study looks at how genes, the cancer environment, and your immune system interact to develop treatments that work better for people with breast cancer. It may help researchers learn why some treatments work for certain people and not others.
New York, New YorkAges 18–90 - NCT05155501Recruiting
Surgery planning approaches for localized prostate cancer
This study compares different approaches used during prostate cancer surgery for men whose cancer is only in the prostate. It may help doctors choose the safest and most effective surgical plan for your situation.
Flushing, New YorkAges 40–80 - NCT05172921Recruiting
Study of environmental factors in thyroid cancer risk
This study looks at how environmental exposures may relate to thyroid cancer. If you have a suspicious thyroid nodule and are planning surgery, your biopsy or surgical tissue may be used to understand risk factors.
New York, New YorkAges 18 years+ - NCT05174286Recruiting
Phone-based coaching to help prevent colon cancer and heart disease
This study uses community health worker support by phone to help people at higher risk stay on top of recommended screening. It may help reduce colorectal cancer risk and also improve heart health.
New York, New YorkAges 45 years+ - NCT05215353RecruitingPhase 4
Music therapy or talk therapy for anxiety after cancer
This study compares music therapy and cognitive behavioral therapy (CBT) to see which better reduces anxiety in people who have had cancer. You may be randomly assigned to one of the two therapy programs and will join sessions by video call.
New York, New YorkAges 18 years+ - NCT05217940Recruiting
Screening women with prior HPV for anal abnormalities
This study looks for early anal cell changes in women who have had high-grade HPV-related problems in the cervix, vagina, or vulva. It may help find concerning changes sooner, using a structured screening exam.
New York, New YorkAges 35 years+ - NCT05231122RecruitingPhase 2
Pembrolizumab and bevacizumab for recurrent ovarian cancer
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
Buffalo, New YorkAges 18 years+ - NCT05239624RecruitingPhase 2
Enfortumab plus pembrolizumab for muscle-invasive bladder cancer
This Phase 2 study tests how well two anti-cancer medicines—enfortumab vedotin and pembrolizumab—work for people with muscle-invasive bladder cancer that has spread to nearby lymph nodes (but not distant organs). It may help shrink the cancer and improve treatment outcomes before or around planning major surgery.
Commack, New YorkAges 18 years+ - NCT05270213RecruitingPhase 1
RBS2418 for advanced cancers after standard treatments
This early-phase study tests RBS2418 in people with advanced, metastatic solid tumors that have not responded to standard treatment. It aims to see if the drug can shrink tumors or help control disease, and to learn what doses are safest.
New York, New YorkAges 18 years+ - NCT05304858Recruiting
Study of prostate cancer spread using biopsy and lab tests
This trial studies the “microenvironment” around prostate cancer metastases, using specimens taken during biopsy and other scans. It may help researchers understand what drives prostate cancer spread and improve future treatment choices.
New York, New YorkAges 18 years+ - NCT05379595RecruitingPhase 1/Phase 2
Amivantamab for advanced colon or rectal cancer with specific tumor traits
This Phase 1/2 study tests amivantamab alone or combined with standard chemotherapy to treat advanced or metastatic colon or rectal cancer. You may be able to join if your tumor has the right genetic profile (typically “wild-type” for certain genes and no HER2 amplification) and your cancer has measurable or biopsy-able lesions.
New York, New YorkAges 18 years+ - NCT05379985RecruitingPhase 1/Phase 2
Test drug RMC-6236 for certain RAS mutations in advanced cancers
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
New York, New YorkAges 18 years+
Cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 8 studies
- Columbia University Irving Medical Center · 5 studies
- Icahn School of Medicine at Mount Sinai · 4 studies
- Memorial Sloan Kettering Nassau · 4 studies
- Memorial Sloan Kettering Commack · 3 studies
- Brooklyn Methodist Hospital - NewYork Presbyterian · 2 studies
- Memorial Sloan Kettering Cancer Center - Westchester · 2 studies
- Memorial Sloan Kettering Westchester · 2 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in New York?
- Yes. We're currently tracking 1,365 recruiting cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.